Literature DB >> 23679157

Epidemiology of ophthalmologic disease associated with erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis in hospitalized children in the United States.

Jacqueline F Moreau1, Robert S Watson, Mary E Hartman, Walter T Linde-Zwirble, Laura K Ferris.   

Abstract

The objective of the current study was to characterize the epidemiology and resource use of U.S. children hospitalized with ophthalmologic disease secondary to erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). We studied children ages 5 to 19 years hospitalized in 2005 in 11 states, encompassing 38% of the U.S. pediatric population. Using International Classification of Diseases, Ninth Revision, Clinical Modification codes, we identified admissions of children with EM, SJS, or TEN and the presence of concurrent ophthalmologic disease, analyzed patient and hospitalization characteristics, and generated age- and sex-adjusted national estimates. We identified 460 children admitted with EM, SJS, or TEN, corresponding to 1,229 U.S. hospitalizations in 2005. Of the children with EM, SJS, or TEN, 60 (13.0%) had ophthalmologic disease, primarily (90.0%) disorders of the conjunctiva. Children with the highest proportions of ophthalmologic disease included those with mycoplasma pneumonia (26.7%), herpes simplex virus (15.6%), upper respiratory infection (13.9%), and lower respiratory infection (13.7%). Individuals with EM, SJS, or TEN and ophthalmologic disease were more likely than those without ophthalmologic disease to receive intensive care unit care (28.3% vs 17.0%, p = 0.03) and to be admitted to a children's hospital (63.3% vs 48.8%, p = 0.03). Ophthalmologic disease was also associated with a significantly longer median length of stay (6.0 days, interquartile range [IQR] 3-9 days vs 3.0 days, IQR 2-6 days, p < 0.001) and median hospital cost ($7,868, IQR $3,539-$17,440 vs $2,969, IQR $1,603-$8,656, p < 0.001). In children with EM, SJS, or TEN, ophthalmologic disease was most common in those with concurrent Mycoplasma pneumoniae and herpes simplex virus infections. Ophthalmologic disease was associated with considerably higher inpatient resource use in this population. Children with EM, SJS, or TEN should be screened and treated early for ophthalmologic disease to prevent morbidity and minimize long-term sequellae.
© 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2013        PMID: 23679157      PMCID: PMC3982228          DOI: 10.1111/pde.12158

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  18 in total

1.  Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry.

Authors:  B Rzany; M Mockenhaupt; S Baur; W Schröder; U Stocker; J Mueller; N Holländer; R Bruppacher; E Schöpf
Journal:  J Clin Epidemiol       Date:  1996-07       Impact factor: 6.437

2.  Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center.

Authors:  Julia Haber; Wilma Hopman; Manuel Gomez; Robert Cartotto
Journal:  J Burn Care Rehabil       Date:  2005 Jan-Feb

Review 3.  Toxic epidermal necrolysis in children: medical, surgical, and ophthalmologic considerations.

Authors:  Sunali Goyal; Punkaj Gupta; Colleen M Ryan; Melanie Kazlas; Natan Noviski; Robert L Sheridan
Journal:  J Burn Care Res       Date:  2009 May-Jun       Impact factor: 1.845

4.  Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985.

Authors:  J C Roujeau; J C Guillaume; J P Fabre; D Penso; M L Fléchet; J P Girre
Journal:  Arch Dermatol       Date:  1990-01

5.  The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients.

Authors:  H L Chan; R S Stern; K A Arndt; J Langlois; S S Jick; H Jick; A M Walker
Journal:  Arch Dermatol       Date:  1990-01

6.  Ophthalmic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis and Relation to SCORTEN.

Authors:  Marlene E Morales; Gary F Purdue; Steven M Verity; Brett D Arnoldo; Preston H Blomquist
Journal:  Am J Ophthalmol       Date:  2010-07-08       Impact factor: 5.258

7.  Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum.

Authors:  W J Power; M Ghoraishi; J Merayo-Lloves; R A Neves; C S Foster
Journal:  Ophthalmology       Date:  1995-11       Impact factor: 12.079

Review 8.  A systematic review of treatment of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children.

Authors:  Blanca R Del Pozzo-Magana; Alejandro Lazo-Langner; Bruce Carleton; Lucila I Castro-Pastrana; Michael J Rieder
Journal:  J Popul Ther Clin Pharmacol       Date:  2011-03-21

9.  The natural history of Stevens Johnson syndrome: patterns of chronic ocular disease and the role of systemic immunosuppressive therapy.

Authors:  M Victoria De Rojas; John K G Dart; Valerie P J Saw
Journal:  Br J Ophthalmol       Date:  2007-02-21       Impact factor: 4.638

10.  Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Julie Gueudry; Jean-Claude Roujeau; Michel Binaghi; Gisèle Soubrane; Marc Muraine
Journal:  Arch Dermatol       Date:  2009-02
View more
  5 in total

Review 1.  Adverse drug reactions - examples of detection of rare events using databases.

Authors:  Esther W Chan; Kirin Q L Liu; Celine S L Chui; Chor-Wing Sing; Lisa Y L Wong; Ian C K Wong
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

Review 2.  SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation.

Authors:  Katie D White; Riichiro Abe; Michael Ardern-Jones; Thomas Beachkofsky; Charles Bouchard; Bruce Carleton; James Chodosh; Ricardo Cibotti; Robert Davis; Joshua C Denny; Roni P Dodiuk-Gad; Elizabeth N Ergen; Jennifer L Goldman; James H Holmes; Shuen-Iu Hung; Mario E Lacouture; Rannakoe J Lehloenya; Simon Mallal; Teri A Manolio; Robert G Micheletti; Caroline M Mitchell; Maja Mockenhaupt; David A Ostrov; Rebecca Pavlos; Munir Pirmohamed; Elena Pope; Alec Redwood; Misha Rosenbach; Michael D Rosenblum; Jean-Claude Roujeau; Arturo P Saavedra; Hajirah N Saeed; Jeffery P Struewing; Hirohiko Sueki; Chonlaphat Sukasem; Cynthia Sung; Jason A Trubiano; Jessica Weintraub; Lisa M Wheatley; Kristina B Williams; Brandon Worley; Wen-Hung Chung; Neil H Shear; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2018 Jan - Feb

Review 3.  Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions.

Authors:  Jason H Karnes; Matthew A Miller; Katie D White; Katherine C Konvinse; Rebecca K Pavlos; Alec J Redwood; Jonathan G Peter; Rannakoe Lehloenya; Simon A Mallal; Elizabeth J Phillips
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-08-22       Impact factor: 13.820

Review 4.  Severe Delayed Drug Reactions: Role of Genetics and Viral Infections.

Authors:  Rebecca Pavlos; Katie D White; Celestine Wanjalla; Simon A Mallal; Elizabeth J Phillips
Journal:  Immunol Allergy Clin North Am       Date:  2017-11       Impact factor: 3.479

5.  Descriptive study of adverse drug reactions in a tertiary care pediatric hospital in México from 2014 to 2017.

Authors:  Olga Morales-Ríos; Carlo Cicero-Oneto; Carlos García-Ruiz; Dina Villanueva-García; Maribelle Hernández-Hernández; Víctor Olivar-López; Rodolfo Norberto Jiménez-Juárez; Luis Jasso-Gutiérrez
Journal:  PLoS One       Date:  2020-03-24       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.